Guerrant says pilot data show this approach has great promise and he plans to collaborate with other UVa scientists and a pharmaceutical company to develop the treatment.
'/>"/>
| Contact: David Foreman davidforeman@virginia.edu 434-924-2242 University of Virginia Health System Source:Eurekalert |